Griffin nct02874742
WebApr 13, 2024 · The phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) evaluated the addition of the anti-CD38 monoclonal antibody daratumumab to RVd (D-RVd) induction and consolidation with ... WebDec 14, 2024 · Findings from the extended 2-year follow-up of the phase 2 GRIFFIN trial (NCT02874742) that were presented during the 63rd American Society of Hematology Annual Meeting and Exposition revealed continued deep and durable responses for patients with transplant-eligible newly diagnosed multiple myeloma when daratumumab …
Griffin nct02874742
Did you know?
WebFeb 4, 2024 · New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with … WebAug 22, 2016 · Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02874742. Locations. Layout table for location information; United States, Alabama: … Recruitment Details: 223 participants were enrolled/randomized (16 in safety run …
WebIntroduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and NDMM.In the primary analysis of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible NDMM, DARA plus RVd (D-RVd) … WebJun 13, 2024 · “The optimal daratumumab-containing maintenance regimen remains to be determined,” Moreau said. “We looked forward to the results of ongoing trials such as …
Web2 days ago · Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, … WebJan 17, 2024 · The answer to both questions is yes, based in part on updated results from the phase 2 GRIFFIN trial (NCT02874742), says Jacob Laubach, MD, MPP, senior …
WebFeb 4, 2024 · New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with newly diagnosed MM, eligible for high-dose therapy and autologous haematopoietic cell transplantation (HCT) were randomised 1:1 to receive daratumumab plus RVd (n=104) …
WebDec 27, 2024 · Officials said the fire caused $657,000 in damage. Four residents and a dog were displaced in a fire in Sterling on Sunday morning. Officials determined that the fire … tim gockeWebAug 27, 2024 · The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with RVd and enrolled and treated more than … tim godardWebJun 11, 2024 · Also, I shed light on some new studies; one of them is the GRIFFIN study [NCT02874742] that builds on the old VRd [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone] paradigm that was developed initially by Paul G. Richardson, MD, and colleagues at the Dana-Farber Cancer Institute. The GRIFFIN study adds daratumumab … tim goblitschke